Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

 Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

Shots:

  • The companies collaborated to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for multiple life-threatening disorders
  • The focus of this agreement is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency
  • The collaboration comes two years after Sirion signed a similar pact with Denali Therapeutics, with other partners including Acucela and Orchard Therapeutics

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post